PT1517710E - Glicoformas do factor vii peguilado - Google Patents
Glicoformas do factor vii peguilado Download PDFInfo
- Publication number
- PT1517710E PT1517710E PT03729912T PT03729912T PT1517710E PT 1517710 E PT1517710 E PT 1517710E PT 03729912 T PT03729912 T PT 03729912T PT 03729912 T PT03729912 T PT 03729912T PT 1517710 E PT1517710 E PT 1517710E
- Authority
- PT
- Portugal
- Prior art keywords
- factor vii
- pegylated factor
- polypeptides
- glycoforms
- linked
- Prior art date
Links
- 229940012413 factor vii Drugs 0.000 title abstract 3
- 229920001184 polypeptide Polymers 0.000 abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 3
- 102100023804 Coagulation factor VII Human genes 0.000 abstract 2
- 108010023321 Factor VII Proteins 0.000 abstract 2
- 239000002202 Polyethylene glycol Substances 0.000 abstract 2
- 150000002482 oligosaccharides Polymers 0.000 abstract 2
- 229920001223 polyethylene glycol Polymers 0.000 abstract 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 abstract 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 abstract 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 abstract 1
- 229960001230 asparagine Drugs 0.000 abstract 1
- 235000009582 asparagine Nutrition 0.000 abstract 1
- 229920001281 polyalkylene Polymers 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Surgery (AREA)
- Pulmonology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200200964 | 2002-06-21 | ||
| US39477802P | 2002-07-01 | 2002-07-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT1517710E true PT1517710E (pt) | 2011-07-08 |
Family
ID=44256861
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT03729912T PT1517710E (pt) | 2002-06-21 | 2003-06-20 | Glicoformas do factor vii peguilado |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP1517710B1 (pt) |
| JP (1) | JP4634145B2 (pt) |
| KR (1) | KR101186140B1 (pt) |
| CN (2) | CN101301475B (pt) |
| AT (1) | ATE503498T1 (pt) |
| AU (1) | AU2003240439B2 (pt) |
| BR (1) | BR0311978A (pt) |
| CA (1) | CA2490360A1 (pt) |
| DK (1) | DK1517710T3 (pt) |
| ES (1) | ES2363205T3 (pt) |
| PL (1) | PL211175B1 (pt) |
| PT (1) | PT1517710E (pt) |
| RU (1) | RU2362807C2 (pt) |
| UA (1) | UA86744C2 (pt) |
| WO (1) | WO2004000366A1 (pt) |
Families Citing this family (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7786070B2 (en) | 1997-09-10 | 2010-08-31 | Novo Nordisk Healthcare A/G | Subcutaneous administration of coagulation factor VII |
| US7214660B2 (en) | 2001-10-10 | 2007-05-08 | Neose Technologies, Inc. | Erythropoietin: remodeling and glycoconjugation of erythropoietin |
| US7157277B2 (en) | 2001-11-28 | 2007-01-02 | Neose Technologies, Inc. | Factor VIII remodeling and glycoconjugation of Factor VIII |
| CN1635901B (zh) * | 2001-10-10 | 2012-03-28 | 诺和诺德公司 | 肽的重构和糖缀合的方法 |
| US7173003B2 (en) | 2001-10-10 | 2007-02-06 | Neose Technologies, Inc. | Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF |
| CA2519092C (en) | 2003-03-14 | 2014-08-05 | Neose Technologies, Inc. | Branched water-soluble polymers and their conjugates |
| EP2338333B1 (en) | 2003-04-09 | 2017-09-06 | ratiopharm GmbH | Glycopegylation methods and proteins/peptides produced by the methods |
| US8791070B2 (en) | 2003-04-09 | 2014-07-29 | Novo Nordisk A/S | Glycopegylated factor IX |
| WO2006127896A2 (en) | 2005-05-25 | 2006-11-30 | Neose Technologies, Inc. | Glycopegylated factor ix |
| WO2005012484A2 (en) | 2003-07-25 | 2005-02-10 | Neose Technologies, Inc. | Antibody-toxin conjugates |
| US20080305992A1 (en) | 2003-11-24 | 2008-12-11 | Neose Technologies, Inc. | Glycopegylated erythropoietin |
| US8633157B2 (en) | 2003-11-24 | 2014-01-21 | Novo Nordisk A/S | Glycopegylated erythropoietin |
| US20060040856A1 (en) | 2003-12-03 | 2006-02-23 | Neose Technologies, Inc. | Glycopegylated factor IX |
| AU2005206796B2 (en) | 2004-01-08 | 2011-06-16 | Ratiopharm Gmbh | O-linked glycosylation of peptides |
| EP1708755B1 (en) * | 2004-01-21 | 2012-03-21 | Novo Nordisk Health Care AG | Transglutaminase mediated conjugation of peptides |
| ES2339953T5 (es) | 2004-05-04 | 2020-05-06 | Novo Nordisk Healthcare Ag | Glicoformas de factor VII ligadas a O y método de fabricación |
| WO2005123916A2 (en) * | 2004-06-21 | 2005-12-29 | Novo Nordisk Health Care Ag | Glycosylation-disrupted factor vii variants |
| WO2006010143A2 (en) | 2004-07-13 | 2006-01-26 | Neose Technologies, Inc. | Branched peg remodeling and glycosylation of glucagon-like peptide-1 [glp-1] |
| EP1799249A2 (en) | 2004-09-10 | 2007-06-27 | Neose Technologies, Inc. | Glycopegylated interferon alpha |
| WO2006035057A1 (en) * | 2004-09-29 | 2006-04-06 | Novo Nordisk Health Care Ag | Modified proteins |
| EP1814573B1 (en) | 2004-10-29 | 2016-03-09 | ratiopharm GmbH | Remodeling and glycopegylation of fibroblast growth factor (fgf) |
| WO2006074279A1 (en) * | 2005-01-06 | 2006-07-13 | Neose Technologies, Inc. | Glycoconjugation using saccharyl fragments |
| JP4951527B2 (ja) | 2005-01-10 | 2012-06-13 | バイオジェネリックス アーゲー | 糖ｐｅｇ化顆粒球コロニー刺激因子 |
| US9187546B2 (en) | 2005-04-08 | 2015-11-17 | Novo Nordisk A/S | Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants |
| US20070105755A1 (en) | 2005-10-26 | 2007-05-10 | Neose Technologies, Inc. | One pot desialylation and glycopegylation of therapeutic peptides |
| KR20080038391A (ko) | 2005-08-30 | 2008-05-06 | 노보 노르디스크 헬스 케어 악티엔게젤샤프트 | 페그화 성장 호르몬의 액체 제제 |
| US20090048440A1 (en) | 2005-11-03 | 2009-02-19 | Neose Technologies, Inc. | Nucleotide Sugar Purification Using Membranes |
| WO2007066775A1 (ja) * | 2005-12-08 | 2007-06-14 | Kaneka Corporation | 外来性遺伝子由来のタンパク質がＧｌａ残基を含むトランスジェニック鳥類及びその作製法 |
| JP5280001B2 (ja) * | 2005-12-08 | 2013-09-04 | 株式会社カネカ | 外来性遺伝子由来のタンパク質がＧｌａ残基を含むトランスジェニック鳥類及びその作製法 |
| US8138272B2 (en) * | 2006-05-22 | 2012-03-20 | Elan Pharmaceuticals, Inc. | Preparation of polymer conjugates of therapeutic, agricultural, and food additive compounds |
| KR20100014215A (ko) | 2006-07-07 | 2010-02-10 | 노보 노르디스크 헬스 케어 악티엔게젤샤프트 | 신규 단백질 접합체 및 그것의 제조 방법 |
| US20080242607A1 (en) | 2006-07-21 | 2008-10-02 | Neose Technologies, Inc. | Glycosylation of peptides via o-linked glycosylation sequences |
| FR2904558B1 (fr) * | 2006-08-01 | 2008-10-17 | Lab Francais Du Fractionnement | "composition de facteur vii recombinant ou transgenique, presentant majoritairement des formes glycanniques biantennees, bisialylees et non fucosylees" |
| US20100056428A1 (en) * | 2006-09-01 | 2010-03-04 | Novo Nordisk Health Care Ag | Modified proteins |
| CN101535339B (zh) * | 2006-09-01 | 2014-11-12 | 诺沃-诺迪斯克保健股份有限公司 | 改性糖蛋白 |
| JP2010505874A (ja) | 2006-10-03 | 2010-02-25 | ノヴォ ノルディスク アー／エス | ポリペプチドコンジュゲートの精製方法 |
| BRPI0717505B8 (pt) * | 2006-10-04 | 2021-05-25 | Novo Nordisk As | conjugado de peptídeo e formulação farmacêutica |
| EP3323430A1 (en) * | 2006-12-15 | 2018-05-23 | Baxalta GmbH | Factor viia-(poly)sialic acid conjugate having prolonged in vivo half-life |
| JP5558106B2 (ja) * | 2007-01-03 | 2014-07-23 | ノボ ノルディスク ヘルス ケア アーゲー | 凝固第ｖｉｉ因子関連ポリペプチドの皮下投与 |
| DK2144923T3 (da) | 2007-04-03 | 2013-05-13 | Biogenerix Ag | Behandlingsfremgangsmåder under anvendelse af glycopegyleret g-csf |
| WO2008135500A1 (en) | 2007-05-02 | 2008-11-13 | Novo Nordisk Health Care Ag | High concentration factor vii polypeptide formulations comprising an aromatic preservative and an antioxidant |
| CA2690611C (en) | 2007-06-12 | 2015-12-08 | Novo Nordisk A/S | Improved process for the production of nucleotide sugars |
| EP2014299A1 (en) * | 2007-07-11 | 2009-01-14 | Novo Nordisk A/S | Subcutaneous administration of coagulation factor VII |
| US8207112B2 (en) | 2007-08-29 | 2012-06-26 | Biogenerix Ag | Liquid formulation of G-CSF conjugate |
| US11197916B2 (en) | 2007-12-28 | 2021-12-14 | Takeda Pharmaceutical Company Limited | Lyophilized recombinant VWF formulations |
| NZ586383A (en) | 2007-12-28 | 2012-11-30 | Baxter Int | Recombinant vwf formulations |
| JP5619630B2 (ja) | 2008-02-27 | 2014-11-05 | ノボ・ノルデイスク・エー／エス | 結合型第ｖｉｉｉ因子分子 |
| TWI465247B (zh) | 2008-04-11 | 2014-12-21 | Catalyst Biosciences Inc | 經修飾的因子ｖｉｉ多肽和其用途 |
| CN102065899A (zh) * | 2008-05-23 | 2011-05-18 | 诺沃-诺迪斯克保健股份有限公司 | 含有高浓度的芳香族防腐剂的peg-官能化的丝氨酸蛋白酶的制剂 |
| KR20110071012A (ko) * | 2008-10-17 | 2011-06-27 | 백스터 인터내셔널 인코포레이티드 | 낮은 수준의 수용성 중합체를 포함하는 개질된 혈액 인자 |
| AR074054A1 (es) | 2008-10-21 | 2010-12-22 | Baxter Healthcare Sa | Formulaciones farmaceuticas de factor de von willebrand recombinante liofilizado |
| US9241896B2 (en) | 2008-12-19 | 2016-01-26 | Ultragenyx Pharmaceutical Inc. | Methods and formulations for treating sialic acid deficiencies |
| ES2590679T3 (es) | 2009-07-27 | 2016-11-23 | Lipoxen Technologies Limited | Glicopolisialilación de proteínas diferentes a proteínas de coagulación de la sangre |
| US8642737B2 (en) | 2010-07-26 | 2014-02-04 | Baxter International Inc. | Nucleophilic catalysts for oxime linkage |
| DK2459224T3 (en) | 2009-07-27 | 2016-07-25 | Baxalta GmbH | Blodstørkningsproteinkonjugater |
| US8809501B2 (en) | 2009-07-27 | 2014-08-19 | Baxter International Inc. | Nucleophilic catalysts for oxime linkage |
| ES2856055T3 (es) | 2009-07-27 | 2021-09-27 | Baxalta GmbH | Glicopolisialilación de proteínas diferentes de las proteínas de coagulación de la sangre |
| WO2011101277A1 (en) * | 2010-02-16 | 2011-08-25 | Novo Nordisk A/S | Conjugated proteins |
| GB201007356D0 (en) * | 2010-04-30 | 2010-06-16 | Leverton Licence Holdings Ltd | Conjugated factor VIIa |
| EP2593109A4 (en) | 2010-07-13 | 2014-01-08 | Ultragenyx Pharmaceutical Inc | METHOD AND FORMULATIONS FOR THE TREATMENT OF SIALIC ACID DEFICIENCIES |
| CN103154233A (zh) | 2010-10-05 | 2013-06-12 | 诺沃—诺迪斯克保健股份有限公司 | 生产蛋白质的方法 |
| WO2012087838A1 (en) | 2010-12-22 | 2012-06-28 | Baxter International Inc. | Materials and methods for conjugating a water soluble fatty acid derivative to a protein |
| BR112014009760B1 (pt) | 2011-10-24 | 2022-11-29 | Ultragenyx Pharmaceutical Inc | Análogos de ácido siálico, seu uso e composição farmacêutica |
| GB201910190D0 (en) * | 2012-04-16 | 2019-08-28 | Cantab Biopharmaceuticals Patents Ltd | Optimised subsutaneous therapeutic agents |
| TW201720803A (zh) | 2015-09-14 | 2017-06-16 | 超基因克斯製藥公司 | 唾液酸或其鹽或溶劑合物之晶型 |
| EP3833381B1 (en) | 2019-08-15 | 2022-08-03 | Catalyst Biosciences, Inc. | Modified factor vii polypeptides for subcutaneous administration |
Family Cites Families (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4456591A (en) | 1981-06-25 | 1984-06-26 | Baxter Travenol Laboratories, Inc. | Therapeutic method for activating factor VII |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| EP0154316B1 (en) | 1984-03-06 | 1989-09-13 | Takeda Chemical Industries, Ltd. | Chemically modified lymphokine and production thereof |
| GB8430252D0 (en) | 1984-11-30 | 1985-01-09 | Beecham Group Plc | Compounds |
| GR860984B (en) | 1985-04-17 | 1986-08-18 | Zymogenetics Inc | Expression of factor vii and ix activities in mammalian cells |
| DE3676670D1 (de) | 1985-06-26 | 1991-02-07 | Cetus Corp | Solubilisierung von proteinen fuer pharmazeutische zusammensetzungen mittels polymerkonjugierung. |
| US4975282A (en) | 1985-06-26 | 1990-12-04 | The Liposome Company, Inc. | Multilamellar liposomes having improved trapping efficiencies |
| US5272066A (en) | 1986-03-07 | 1993-12-21 | Massachusetts Institute Of Technology | Synthetic method for enhancing glycoprotein stability |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US4847325A (en) | 1988-01-20 | 1989-07-11 | Cetus Corporation | Conjugation of polymer to colony stimulating factor-1 |
| GB8824591D0 (en) | 1988-10-20 | 1988-11-23 | Royal Free Hosp School Med | Fractionation process |
| CA2006596C (en) | 1988-12-22 | 2000-09-05 | Rika Ishikawa | Chemically-modified g-csf |
| US4902502A (en) | 1989-01-23 | 1990-02-20 | Cetus Corporation | Preparation of a polymer/interleukin-2 conjugate |
| WO1990013540A1 (en) | 1989-04-19 | 1990-11-15 | Enzon, Inc. | Active carbonates of polyalkylene oxides for modification of polypeptides |
| US5122614A (en) | 1989-04-19 | 1992-06-16 | Enzon, Inc. | Active carbonates of polyalkylene oxides for modification of polypeptides |
| ATE136315T1 (de) | 1989-05-27 | 1996-04-15 | Sumitomo Pharma | Verfahren für die herstellung von polyethylenglykolderivate und modifizierte proteine. |
| US5580560A (en) | 1989-11-13 | 1996-12-03 | Novo Nordisk A/S | Modified factor VII/VIIa |
| US5219564A (en) | 1990-07-06 | 1993-06-15 | Enzon, Inc. | Poly(alkylene oxide) amino acid copolymers and drug carriers and charged copolymers based thereon |
| WO1992008790A1 (en) | 1990-11-14 | 1992-05-29 | Cargill, Incorporated | Conjugates of poly(vinylsaccharide) with proteins for the stabilization of proteins |
| US5997864A (en) | 1995-06-07 | 1999-12-07 | Novo Nordisk A/S | Modified factor VII |
| CA2101918A1 (en) | 1991-03-18 | 1992-09-19 | Samuel Zalipsky | Hydrazine containing conjugates of polypeptides and glycopolypeptides with polymers |
| US5595732A (en) | 1991-03-25 | 1997-01-21 | Hoffmann-La Roche Inc. | Polyethylene-protein conjugates |
| US5212075A (en) | 1991-04-15 | 1993-05-18 | The Regents Of The University Of California | Compositions and methods for introducing effectors to pathogens and cells |
| US5281698A (en) | 1991-07-23 | 1994-01-25 | Cetus Oncology Corporation | Preparation of an activated polymer ester for protein conjugation |
| ZA933926B (en) | 1992-06-17 | 1994-01-03 | Amgen Inc | Polyoxymethylene-oxyethylene copolymers in conjuction with blomolecules |
| AU5006993A (en) | 1992-08-21 | 1994-03-15 | Enzon, Inc. | Novel attachment of polyalkylene oxides to bio-effecting substances |
| US5382657A (en) | 1992-08-26 | 1995-01-17 | Hoffmann-La Roche Inc. | Peg-interferon conjugates |
| NZ250375A (en) | 1992-12-09 | 1995-07-26 | Ortho Pharma Corp | Peg hydrazone and peg oxime linkage forming reagents and protein derivatives |
| US5298643A (en) | 1992-12-22 | 1994-03-29 | Enzon, Inc. | Aryl imidate activated polyalkylene oxides |
| US5349001A (en) | 1993-01-19 | 1994-09-20 | Enzon, Inc. | Cyclic imide thione activated polyalkylene oxides |
| US5321095A (en) | 1993-02-02 | 1994-06-14 | Enzon, Inc. | Azlactone activated polyalkylene oxides |
| IL104734A0 (en) | 1993-02-15 | 1993-06-10 | Univ Bar Ilan | Bioactive conjugates of cellulose with amino compounds |
| US5374541A (en) | 1993-05-04 | 1994-12-20 | The Scripps Research Institute | Combined use of β-galactosidase and sialyltransferase coupled with in situ regeneration of CMP-sialic acid for one pot synthesis of oligosaccharides |
| AU7097094A (en) | 1993-06-01 | 1994-12-20 | Enzon, Inc. | Carbohydrate-modified polymer conjugates with erythropoietic activity |
| WO1995000162A1 (en) | 1993-06-21 | 1995-01-05 | Enzon, Inc. | Site specific synthesis of conjugated peptides |
| GB9317618D0 (en) | 1993-08-24 | 1993-10-06 | Royal Free Hosp School Med | Polymer modifications |
| US5643575A (en) | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| US5919455A (en) | 1993-10-27 | 1999-07-06 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| US5951974A (en) | 1993-11-10 | 1999-09-14 | Enzon, Inc. | Interferon polymer conjugates |
| US5711944A (en) | 1993-11-10 | 1998-01-27 | Enzon, Inc. | Interferon polymer conjugates |
| US5446090A (en) * | 1993-11-12 | 1995-08-29 | Shearwater Polymers, Inc. | Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules |
| US5473034A (en) | 1994-03-18 | 1995-12-05 | Hyogo Prefectural Government | Method for producing protein-synthetic polymer conjugate and said conjugate produced thereby |
| US5629384A (en) | 1994-05-17 | 1997-05-13 | Consiglio Nazionale Delle Ricerche | Polymers of N-acryloylmorpholine activated at one end and conjugates with bioactive materials and surfaces |
| AU2826495A (en) | 1994-06-02 | 1996-01-04 | Enzon, Inc. | Method of solubilizing substantially water insoluble materials |
| US5730990A (en) | 1994-06-24 | 1998-03-24 | Enzon, Inc. | Non-antigenic amine derived polymers and polymer conjugates |
| US5650234A (en) | 1994-09-09 | 1997-07-22 | Surface Engineering Technologies, Division Of Innerdyne, Inc. | Electrophilic polyethylene oxides for the modification of polysaccharides, polypeptides (proteins) and surfaces |
| EP0788375A2 (en) | 1994-11-09 | 1997-08-13 | Robin Ewart Offord | Functionalized polymers for site-specific attachment |
| US5738846A (en) | 1994-11-10 | 1998-04-14 | Enzon, Inc. | Interferon polymer conjugates and process for preparing the same |
| US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
| WO1996040791A1 (en) | 1995-06-07 | 1996-12-19 | Novo Nordisk A/S | Modification of polypeptides |
| US5672662A (en) | 1995-07-07 | 1997-09-30 | Shearwater Polymers, Inc. | Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications |
| US5747639A (en) | 1996-03-06 | 1998-05-05 | Amgen Boulder Inc. | Use of hydrophobic interaction chromatography to purify polyethylene glycols |
| TW517067B (en) | 1996-05-31 | 2003-01-11 | Hoffmann La Roche | Interferon conjugates |
| EP0964702B1 (en) | 1996-08-02 | 2006-10-04 | Ortho-McNeil Pharmaceutical, Inc. | Polypeptides having a single covalently bound n-terminal water-soluble polymer |
| DE69823046T2 (de) | 1997-01-16 | 2005-03-31 | Neose Technologies, Inc. | Praktische in vitro sialylierung von rekombinanten glykpproteinen |
| EP0921817B1 (en) * | 1997-01-29 | 2001-03-28 | PolyMASC Pharmaceuticals plc | Pegylation process |
| CA2288992C (en) | 1997-04-30 | 2012-06-12 | Enzon, Inc. | Single-chain antigen-binding proteins capable of glycosylation, production and uses thereof |
| US6583267B2 (en) | 1997-06-06 | 2003-06-24 | Kyowa Hakko Kogyo Co., Ltd. | Chemically modified polypeptides |
| US5981709A (en) | 1997-12-19 | 1999-11-09 | Enzon, Inc. | α-interferon-polymer-conjugates having enhanced biological activity and methods of preparing the same |
| US5985263A (en) | 1997-12-19 | 1999-11-16 | Enzon, Inc. | Substantially pure histidine-linked protein polymer conjugates |
| PT1257295E (pt) * | 2000-02-11 | 2009-07-16 | Bayer Healthcare Llc | Moléculas de tipo factor vii ou viia |
| EP1282693B1 (en) | 2000-05-03 | 2010-10-20 | Novo Nordisk Health Care AG | Human coagulation factor vii variants |
| US6423826B1 (en) * | 2000-06-30 | 2002-07-23 | Regents Of The University Of Minnesota | High molecular weight derivatives of vitamin K-dependent polypeptides |
| PL204888B1 (pl) | 2000-09-13 | 2010-02-26 | Novo Nordisk Healthcare Ag | Wariant polipeptydu czynnika VII, konstrukcja kwasu nukleinowego, rekombinowana komórka gospodarza, zwierzę transgeniczne, sposób wytwarzania wariantu polipeptydu czynnika VII, kompozycja farmaceutyczna i zastosowanie wariantu polipeptydu czynnika VII |
| JP4477299B2 (ja) | 2000-10-02 | 2010-06-09 | ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト | 因子ｖｉｉグリコ型 |
| JP2004529640A (ja) | 2001-03-22 | 2004-09-30 | ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト | 第ｖｉｉ凝固因子誘導体 |
| CA2461003A1 (en) | 2001-09-27 | 2003-04-03 | Novo Nordisk Health Care Ag | Human coagulation factor vii polypeptides |
| ES2490590T3 (es) | 2001-11-02 | 2014-09-04 | Novo Nordisk Health Care Ag | Polipéptidos de factor VII de coagulación humana |
-
2003
- 2003-06-20 RU RU2005101348/13A patent/RU2362807C2/ru not_active IP Right Cessation
- 2003-06-20 KR KR1020047020875A patent/KR101186140B1/ko not_active Expired - Fee Related
- 2003-06-20 JP JP2004530894A patent/JP4634145B2/ja not_active Expired - Fee Related
- 2003-06-20 ES ES03729912T patent/ES2363205T3/es not_active Expired - Lifetime
- 2003-06-20 WO PCT/DK2003/000420 patent/WO2004000366A1/en active Application Filing
- 2003-06-20 UA UA20041210113A patent/UA86744C2/ru unknown
- 2003-06-20 PL PL374318A patent/PL211175B1/pl not_active IP Right Cessation
- 2003-06-20 EP EP03729912A patent/EP1517710B1/en not_active Revoked
- 2003-06-20 AT AT03729912T patent/ATE503498T1/de active
- 2003-06-20 DK DK03729912.0T patent/DK1517710T3/da active
- 2003-06-20 CN CN2008100094681A patent/CN101301475B/zh not_active Expired - Fee Related
- 2003-06-20 PT PT03729912T patent/PT1517710E/pt unknown
- 2003-06-20 AU AU2003240439A patent/AU2003240439B2/en not_active Ceased
- 2003-06-20 CN CNA038174170A patent/CN1671420A/zh active Pending
- 2003-06-20 CA CA002490360A patent/CA2490360A1/en not_active Abandoned
- 2003-06-20 BR BR0311978-5A patent/BR0311978A/pt not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| CN1671420A (zh) | 2005-09-21 |
| BR0311978A (pt) | 2005-03-22 |
| AU2003240439A1 (en) | 2004-01-06 |
| CN101301475B (zh) | 2012-12-19 |
| JP4634145B2 (ja) | 2011-02-16 |
| DK1517710T3 (da) | 2011-07-18 |
| UA86744C2 (en) | 2009-05-25 |
| ES2363205T3 (es) | 2011-07-26 |
| KR20050016612A (ko) | 2005-02-21 |
| WO2004000366A1 (en) | 2003-12-31 |
| CA2490360A1 (en) | 2003-12-31 |
| ATE503498T1 (de) | 2011-04-15 |
| RU2362807C2 (ru) | 2009-07-27 |
| KR101186140B1 (ko) | 2012-09-27 |
| EP1517710A1 (en) | 2005-03-30 |
| PL374318A1 (en) | 2005-10-17 |
| EP1517710B1 (en) | 2011-03-30 |
| AU2003240439B2 (en) | 2009-05-21 |
| CN101301475A (zh) | 2008-11-12 |
| RU2005101348A (ru) | 2005-08-27 |
| PL211175B1 (pl) | 2012-04-30 |
| JP2006513142A (ja) | 2006-04-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL374318A1 (en) | Pegylated factor vii glycoforms | |
| NO20050324L (no) | Pegylerte faktor-VII-glykoformer | |
| WO2004043474A3 (de) | Verwendung eines oder mehrerer der elemente aus der gruppe yttrium, neodym und zirconium | |
| IL161229A0 (en) | Methods and compositions relating to restricted expression lentiviral vectors and their applications. | |
| PL368462A1 (en) | Clear and flexible propylene polymer compositions | |
| AU4012100A (en) | Pseudotyped lentiviral vectors and uses thereof | |
| WO2000023114A3 (en) | Polymer conjugates of interferon beta- 1a and their uses | |
| HUP0103265A3 (en) | Cyclic prosaposin-derived peptides, pharmaceutical compositions comprising thereof and their use | |
| ZA200204603B (en) | Amphiphilic polymers and polypeptide conjugates comprising same. | |
| HUP0500457A3 (en) | Polyalkylene polymer compounds, compositions containing the same and uses thereof | |
| IL159627A0 (en) | T-cell regulatory genes and diagnostic methods utilizing the same | |
| AU2002345544A1 (en) | Method of immobilizing a biologic in a polyurethane-hydrogel composition, a composition prepared from the method, and biomedical applications | |
| IL164552A0 (en) | Binary or polynary targeting and uses thereof | |
| AU2002311794A1 (en) | Modular molecular clasps and uses thereof | |
| EP1362429A4 (en) | CARTESIC GRINDING SYSTEMS WITH DIGITAL PROCESSING | |
| AU8738401A (en) | Novel kallikrein gene | |
| WO2003048205A3 (fr) | Proteines a activite inhibitrice de l'il-6 | |
| ZA200209394B (en) | Polymer modified gypsum membrane and uses therefor. | |
| EP1356858B8 (en) | Reactor and use thereof for solution polymerization and bulk polymerization | |
| GB0017955D0 (en) | Novel photoresist monomers,polymers thereof,and photoresist compositions containing the same | |
| AU6063900A (en) | Novel genes encoding proteins having prognostic, diagnostic, preventive, therapeutic, and other uses | |
| SG185137A1 (en) | Biologically active peptides | |
| AU1509501A (en) | A novel polypeptide, a human deafness-related gene 14 and the polynucleotide encoding the polypeptide | |
| FR2828687B1 (fr) | Nouveaux peptides et leur utilisation comme medicaments contre l'infection par le fiv chez le chat | |
| AU5619700A (en) | Novel genes encoding proteins having diagnostic, preventive, therapeutic, and other uses |